Common Long-Term Effects on Liver and Lungs
Methotrexate, used for rheumatoid arthritis, psoriasis, and cancer, can cause progressive liver damage over years of use. Fibrosis or cirrhosis develops in 5-25% of patients on low-dose therapy (7.5-25 mg/week), with risk rising after cumulative doses exceed 1.5-3.5 grams. Regular liver biopsies or non-invasive tests like FibroScan monitor this; alcohol use or obesity accelerates damage [1][2].
Pulmonary toxicity, including interstitial pneumonitis, affects 1-11% of users, potentially leading to chronic fibrosis and reduced lung function. Symptoms like dry cough and dyspnea may appear after months to years, resolving in some upon discontinuation but causing permanent impairment in others [1][3].
Bone Marrow and Blood Risks
Chronic suppression of bone marrow leads to anemia, leukopenia, or thrombocytopenia in up to 10-30% of long-term patients. This increases infection risk and may require dose adjustments or folate supplementation (1 mg/day) to mitigate [1][2].
Cancer and Reproductive Concerns
Elevated risk of lymphoma (standardized incidence ratio 2-4 times higher) and skin cancers, particularly non-melanoma types, after prolonged exposure. Mechanism involves folate antagonism disrupting DNA synthesis [2][3].
Fertility impacts include ovarian failure in women (dose-dependent, higher with >10 g cumulative) and sperm abnormalities in men, though most recover post-treatment. Teratogenicity persists; pregnancy contraindicated for 3-6 months after stopping [1][4].
Kidney, GI, and Neurological Effects
Nephrotoxicity causes chronic kidney injury via crystal precipitation, more common at high doses but seen in 1-5% of rheumatoid arthritis patients long-term. Hydration and leucovorin rescue help prevent [3].
Gastrointestinal issues like mucositis evolve into chronic ulcers or malabsorption. Nodulosis (rheumatoid nodules) worsens in 10-20% [2].
Neurological effects include cognitive decline or "methotrexate leukoencephalopathy" in high-dose regimens, with white matter changes on MRI [3].
Monitoring and Risk Reduction Strategies
Baseline and every 1-3 month checks of liver enzymes, CBC, creatinine, and chest X-rays recommended. Folate co-administration cuts toxicity by 70-80% without losing efficacy. Discontinue if fibrosis advances [1][2][4].
Higher risks in diabetes, obesity, or alcohol users; lowest with <15 mg/week doses [2].
Differences by Dose and Condition
Low-dose weekly (rheumatoid arthritis/psoriasis): Liver/lung focus, 1-5% severe events over 5-10 years.
High-dose IV (cancer): Acute but cumulative neuro/nephrotoxicity dominates long-term [3].
Sources:
[1] NEJM: Methotrexate Toxicity (2014)
[2] Annals Rheum Dis: Long-term safety (2020)
[3] UpToDate: Methotrexate Overview
[4] StatPearls: Methotrexate (2023)